1
|
Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskiy D, Pikiel J, Eniu A, Komov D, Lee S, Kim M, Kim S, Park S, Bae J, Esteva F. 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
2
|
Kolyadina I, Ganshina I, Zhukova L, Abdullaev A, Komov D, Poddubnaya I, Pavlikova O, Vishnevskaya Y, Kozlov N, Khokhlova S. The first results of neoadjuvant therapy with the biosimilar of trastuzumab in HER2+ breast cancer stage II-III in routine Russian practice. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30547-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
3
|
Esteva F, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskiy D, Pikiel J, Eniu A, Komov D, Zautashvili Z, Morar-Bolba G, Li R, Lifirenko I, Rusyn A, Lee S, Yu S, Stebbing J. Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx362.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Ramalingam S, Goss G, Rosell R, Schmid-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T, Khuri F, Samarzija M, Felip E, Ciuleanu T, Hirsh V, Wehler T, Spicer J, Salgia R, Shapiro G, Sheldon E, Teofilovici F, Vukovic V, Fennell D. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Ann Oncol 2015; 26:1741-8. [PMID: 25997818 DOI: 10.1093/annonc/mdv220] [Citation(s) in RCA: 82] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2015] [Accepted: 04/28/2015] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND This trial was designed to evaluate the activity and safety of ganetespib in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) and to identify patient populations most likely to benefit from the combination. PATIENTS AND METHODS Patients with one prior systemic therapy for advanced disease were eligible. Docetaxel (75 mg/m(2) on day 1) was administered alone or with ganetespib (150 mg/m(2) on days 1 and 15) every 3 weeks. The primary end points were progression-free survival (PFS) in two subgroups of the adenocarcinoma population: patients with elevated lactate dehydrogenase (eLDH) and mutated KRAS (mKRAS). RESULTS Of 385 patients enrolled, 381 were treated. Early in the trial, increased hemoptysis and lack of efficacy were observed in nonadenocarcinoma patients (n = 71); therefore, only patients with adenocarcinoma histology were subsequently enrolled. Neutropenia was the most common grade ≥3 adverse event: 41% in the combination arm versus 42% in docetaxel alone. There was no improvement in PFS for the combination arm in the eLDH (N = 114, adjusted hazard ratio (HR) = 0.77, P = 0.1134) or mKRAS (N = 89, adjusted HR = 1.11, P = 0.3384) subgroups. In the intent-to-treat adenocarcinoma population, there was a trend in favor of the combination, with PFS (N = 253, adjusted HR = 0.82, P = 0.0784) and overall survival (OS) (adjusted HR = 0.84, P = 0.1139). Exploratory analyses showed significant benefit of the ganetespib combination in the prespecified subgroup of adenocarcinoma patients diagnosed with advanced disease >6 months before study entry (N = 177): PFS (adjusted HR = 0.74, P = 0.0417); OS (adjusted HR = 0.69, P = 0.0191). CONCLUSION Advanced lung adenocarcinoma patients treated with ganetespib in combination with docetaxel had an acceptable safety profile. While the study's primary end points were not met, significant prolongation of PFS and OS was observed in patients >6 months from diagnosis of advanced disease, a subgroup chosen as the target population for the phase III study.
Collapse
Affiliation(s)
- S Ramalingam
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, USA
| | - G Goss
- Division of Medical Oncology, University of Ottawa, Ottawa, Canada
| | - R Rosell
- Medical Oncology Service, Catalan Institute of Oncology, Badalona, Spain
| | - G Schmid-Bindert
- Department of Surgery, University Medical Center Mannheim, Mannheim, Germany
| | - B Zaric
- Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad
| | - Z Andric
- Clinic for Oncology, Medical Center Bezanijska Kosa, Belgrade, Serbia
| | - I Bondarenko
- Department of Oncology, Multiple-Discipline Clinical Hospital #4, Dnipropetrovsk, Ukraine
| | - D Komov
- Surgical Department of Tumor Diagnostics, Russian Academy of Medical Science, Moscow, Russia
| | - T Ceric
- Oncology Clinic, University of Sarajevo Clinics Center, Sarajevo, Bosnia
| | - F Khuri
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, USA
| | - M Samarzija
- Department for Respiratory Diseases Jordanovac, University of Zagreb, Zagreb, Croatia
| | - E Felip
- Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - T Ciuleanu
- Department of Medical Oncology, Oncological Institute Ion Chiricuta, Cluj-Napoca, Romania
| | - V Hirsh
- Department of Medical Oncology, McGill University Health Centre, Montreal, Canada
| | - T Wehler
- Third Department of Internal Medicine, Johannes Gutenberg-University of Mainz, Mainz, Germany
| | - J Spicer
- Department of Research Oncology, King's College London, London, UK
| | - R Salgia
- Department of Medicine, University of Chicago, Chicago
| | - G Shapiro
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston
| | - E Sheldon
- Department of Clinical Research, Synta Pharmaceuticals Corp., Lexington, USA
| | - F Teofilovici
- Department of Clinical Research, Synta Pharmaceuticals Corp., Lexington, USA
| | - V Vukovic
- Department of Clinical Research, Synta Pharmaceuticals Corp., Lexington, USA
| | - D Fennell
- Department of Cancer Studies, University of Leicester, Leicester, UK
| |
Collapse
|
5
|
Kolyadina IV, Kuppen PJK, Van De Velde CJH, Poddubnaya IV, Dekker-Ensink N, Prinse B, Frank G, Karseladze A, Komov D, Engles C, Ermilova V. Prognostic and predictable value of COX2 expression in Russian women with stage I breast cancer. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.26_suppl.80] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
80 Background: Some previous studies found worse prognosis among cyclooxygenase-2 (COX2)-expressing breast cancers; we study prognostic and predictiable value of COX2 expression in breast cancer stage I. Methods: our study included Russian women with breast cancer stage I (n=315) treated in RCRC, RMAPE (1985-2009). A Tissue Micro Array (TMA) with triplicate 1 mm tumor tissue punches taken from tumor blocks was constructed in LUMC; sections were immunohistochemically stained for ER, PR, HER2-status, Ki67 (by standard morphological criteria); COX2-expression were evaluated as positive (>median; 31/309 cases, 10%) or negative (≤median; 278/209 cases, 90%). Also the histological type, grade, age and adjuvant endocrine therapy were examined. We analyzed the clinic and morphological data of COX2-positive tumors, prognostic value for survival (relapses free- RFS, overall- OS and cancer specific- CSS) and predictable value for endocrine therapy. Results: COX2-positive tumor were associated with ductal histological type (p=0,018), PR-negative status (p=0,027) and high Ki67 (p<0,0001), but not correlated (p>0,05) with age, grade, ER, HER2 status or biological subtype. In women with ER-negative tumors (104 patients, 34,1%) COX2-expression did not associate with worse survival (p>0,05). In contrast to this, in patients with ER-positive tumors (201 women, 65,9%) COX2-expression strongly correlated with worse RFS in univariate (HR 2,829, 95% CI 1,366-5,860, p=0,005) and multivariate analyses (HR=2,972, 95% CI 1,190-7,423, p=0,02). The same value of COX2-expression in women with ER-positive tumors was found for CSS (univariate: HR 3,421, 95% CI 1,436-8,149, p=0,005; multivariate: HR 4,260, 95% CI 1,344-13,504, p=0,014), but not for OS (p>0,05). In women who did not receive adjuvant endocrine therapy (145 patients, 46%) COX2 expression did not have any prognostic value for RFS, OS and CSS (p>0,05) but in patients that used adjuvant endocrine therapy (170 women, 54%) COX2-expression strongly associated with worse cancer-specific survival (HR 5,614 95% CI 1,165-27,059, p=0,032), but not with RFS and OS (p>0,05). Conclusions: COX2 expression plays a role in hormonal pathways and sensitivity for endocrine therapy.
Collapse
Affiliation(s)
| | | | | | | | | | - B. Prinse
- Leiden University Medical Center, Leiden, Netherlands
| | - G. Frank
- Russian Medical Academy for Postgraduate Education Russian Cancer Reseach Center, Moscow, Russia
| | - A. Karseladze
- Russian Medical Academy for Postgraduate Education Russian Cancer Reseach Center, Moscow, Russia
| | - D. Komov
- Russian Medical Academy for Postgraduate Education Russian Cancer Reseach Center, Moscow, Russia
| | - C. Engles
- Leiden University Medical Center, Leiden, Netherlands
| | - V. Ermilova
- Russian Medical Academy for Postgraduate Education Russian Cancer Reseach Center, Moscow, Russia
| |
Collapse
|
6
|
Kolyadina I, Kuppen P, van de Velde C, Dekker-Ensink N, Bastiaannet E, Prinse B, Engels C, Karseladze A, Poddubnaya I, Ermilova V, Komov D, Frank G. Clinical and Morphological Characteristics of P53-Positive Breast Cancer Stage I in Russian and Dutch Populations. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu327.36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Kolyadina IV, Kuppen PJK, Van De Velde CJH, Poddubnaya I, Dekker-Ensink N, Sajet A, Engels C, Karseladze A, Frank G, Komov D, Ermilova V. Prognostic value of classical HLA class I and nonclassical HLA-E in Russian and Dutch patients with breast cancer stage I. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e22095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Peter JK Kuppen
- Department of Surgical Oncology, Leiden University Medical Center, Leiden, Netherlands
| | | | - Irina Poddubnaya
- Russian Medical Academy for Postgraduate Education Russian Cancer Reseach Center, Moscow, Russia
| | | | - A. Sajet
- Leiden University Medical Center, Leiden, Netherlands
| | - C. Engels
- Leiden University Medical Center, Leiden, Netherlands
| | - A. Karseladze
- Russian Medical Academy for Postgraduate Education Russian Cancer Reseach Center, Moscow, Russia
| | - G. Frank
- Russian Medical Academy for Postgraduate Education Russian Cancer Reseach Center, Moscow, Russia
| | - D. Komov
- Russian Medical Academy for Postgraduate Education Russian Cancer Reseach Center, Moscow, Russia
| | - V. Ermilova
- Russian Medical Academy for Postgraduate Education Russian Cancer Reseach Center, Moscow, Russia
| |
Collapse
|